title: Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.
abstract: OBJECTIVE
  To evaluate the safety of up to 3 years of pegaptanib sodium therapy in the treatment of neovascular age-related macular degeneration (NV-AMD).
  
  
  METHODS
  Two concurrent, prospective, multicentre, double-masked studies randomised subjects with all angiographic lesion compositions of NV-AMD to receive intravitreous pegaptanib sodium (0.3, 1 and 3 mg) or sham injections every 6 weeks for 54 weeks. Those initially assigned to pegaptanib were rerandomised to continue or discontinue therapy for 48 more weeks; sham-treated subjects continued sham, discontinued or received pegaptanib. At 102 weeks, subjects receiving pegaptanib 0.3 mg or 1 mg in years 1 or 2 continued; those receiving pegaptanib 3 mg or who did not receive treatment in years 1 and 2 were rerandomised to 0.3 mg or 1 mg for year 3.
  
  
  RESULTS
  As in years 1 and 2, pegaptanib was well tolerated in year 3. Adverse events were mainly ocular in nature, mild, transient and injection-related. Serious adverse events were rare. No evidence of systemic safety signals attributed to vascular endothelial growth factor inhibition arose in year 3. There were no findings in relation to vital signs or electrocardiogram results suggesting a relationship to pegaptanib treatment.
  
  
  CONCLUSIONS
  The 3-year safety profile of pegaptanib sodium was favourable in patients with NV-AMD.
authors.affiliation: Retina Associates of Cleveland, 3401 Enterprise Parkway, Suite 300, Cleveland, OH 44122, USA. lsingerman@retina-assoc.com
authors.forename: L J
authors.initials: LJ
authors.lastname: Singerman
authors.forename: H
authors.initials: H
authors.lastname: Masonson
authors.forename: M
authors.initials: M
authors.lastname: Patel
authors.forename: A P
authors.initials: AP
authors.lastname: Adamis
authors.forename: R
authors.initials: R
authors.lastname: Buggage
authors.forename: E
authors.initials: E
authors.lastname: Cunningham
authors.forename: M
authors.initials: M
authors.lastname: Goldbaum
authors.forename: B
authors.initials: B
authors.lastname: Katz
authors.forename: D
authors.initials: D
authors.lastname: Guyer
mesh_terms: D000368:Aged; D052157:Aptamers, Nucleotide / Q000009:adverse effects*; D020256:Choroidal Neovascularization / Q000517:prevention & control*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D014065:Tonometry, Ocular; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib